A 57-year-old man was diagnosed with myelodysplastic syndrome (refractory anemia with excess blasts [RAEB]-2) in April, 2007. As leukopenia gradually aggravated along with pneumonia overlap, we suspended the 12 th cycle of azacitidine therapy and administered intermittent transfusion therapy. Biochemical profiles for iron metabolism, including serum iron (166 μg/dL), total iron binding capacity (188 μg/dL), transferrin saturation (88.30%), and ferritin (3,223 μg/dL), showed iron overload because of prolonged transfusion therapy. However, transfusion therapy was inevitably continued with administration of an iron chelating agent. The patient also received at least 100 units of packed RBCs and 48 units of platelet concentrates. Follow-up bone marrow study in December 2010 showed fibrosis and markedly increased cellularity, which mostly consisted of histiocytes with extremely high iron load.
